Myriad Pharmaceuticals, Inc. Names Vice President of Marketing
Jose Fojas to Head All Therapeutic Marketing Activities
SALT LAKE CITY, March 8 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc.
(Nasdaq: MYGN) (www.myriad.com ) announced today that Jose Fojas has been
appointed Vice President of Marketing for Myriad Pharmaceuticals, Inc.
Mr. Fojas will oversee all aspects of marketing therapeutic compounds at
Myriad, including marketing plans, forecasts and pricing. Initially, he will
refine and execute the marketing strategy for Myriad's two lead drug
candidates, Flurizan(TM), for the treatment of Alzheimer's disease and
MPC-6827 for the treatment of metastatic brain tumors. Mr. Fojas will also
initiate plans for the Company's blood cancer drug candidate and its two
compounds that are scheduled for Investigational New Drug application this
calendar year for AIDS and thrombosis.
Mr. Fojas was previously with Eisai, Inc., where he served as Group
Franchise Director for the Critical Care and Oncology Groups of the $2 Billion
United States arm of Eisai Co., Ltd., a USD$4.3 Billion global operation with
headquarters in Japan. In his eight years with Eisai, Mr. Fojas served in
various marketing and sales management positions, including management of
drugs in the Alzheimer's disease, oncology, acute care and epilepsy markets.
Prior to Eisai, Mr. Fojas managed products in the Oncology field for Schein
Pharmaceutical and Purdue Frederick. Mr. Fojas received his Bachelor's degree
in Zoology from Miami University of Oxford, Ohio.
"It is with a great deal of pleasure that I welcome Jose to Myriad," said
Wayne Laslie, Chief Commercial Officer and Chief Operations Officer of Myriad
Pharmaceuticals, Inc. "His strong marketing experience in areas of direct and
immediate relevance to Myriad, includes a background well-suited to maximizing
the potential of our full pipeline of drug candidates as we move them toward
commercialization."
Myriad Genetics, Inc. is a biopharmaceutical company focused on the
development and marketing of novel healthcare products. The Company develops
and markets predictive medicine products, and is developing and intends to
market therapeutic products. Myriad's news and other information are
available on the Company's Web site at www.myriad.com.
Flurizan is a trademark of Myriad Genetics, Inc. in the United States and
other countries. All other trademarks mentioned are the property of their
respective owners.
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include the scheduling of two compounds for
Investigational New Drug application this year. These forward-looking
statements are based on management's current expectation and are subject to
certain risks and uncertainties that could cause actual results to differ
materially from those set forth or implied by forward-looking statements.
These include, but are not limited to, uncertainties as to the extent of
future government regulation of Myriad Genetics' business; uncertainties as to
whether Myriad Genetics and its collaborators will be successful in
developing, and obtaining regulatory approval for, and commercial acceptance
of, therapeutic compounds; the risk that markets will not exist for
therapeutic compounds that Myriad Genetics develops or if such markets exist,
that Myriad Genetics will not be able to sell compounds, which it develops, at
acceptable prices; and the risk that the Company will not be able to sustain
revenue growth for its predictive medicine business and products. These and
other risks are identified in the Company's filings with the Securities and
Exchange Commission, including the Company's current Report on Form 8-K filed
October 28, 2005. All information in this press release is as of
March 8, 2006 and Myriad undertakes no duty to update this information unless
required by law.
SOURCE Myriad Genetics, Inc.
-0- 03/08/2006
/CONTACT: William A. Hockett, EVP, Communications of Myriad Genetics,
Inc., +1-801-584-3600, bhockett@myriad.com/
/Web site: http://www.myriad.com /
(MYGN)
CO: Myriad Genetics, Inc.; Myriad Pharmaceuticals, Inc.
ST: Utah
IN: HEA MTC
SU: PER
KM-MS
-- LAW047 --
9567 03/08/2006 06:30 EST http://www.prnewswire.com
|
